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Abstract
Clostridium botulinum neurotoxins are used to treat a variety of neuro-muscular disorders, as well as in cosmetology. The
increased demand requires efficient methods for the production and purification of these toxins. In this study, a new
purification process was developed for purifying type B neurotoxin. The kinetics of C.botulinum strain growth and
neurotoxin production were determined for maximum yield of toxin. The neurotoxin was purified by polyethylene glycol
(PEG) precipitation and chromatography. Based on design of full factorial experiment, 20% (w/v) PEG-6000, 4uC, pH 5.0 and
0.3 M NaCl were optimal conditions to obtain a high recovery rate of 87% for the type B neurotoxin complex, as indicated
by a purification factor of 61.5 fold. Furthermore, residual bacterial cells, impurity proteins and some nucleic acids were
removed by PEG precipitation. The following purification of neurotoxin was accomplished by two chromatography
techniques using Sephacryl
TM S-100 and phenyl HP columns. The neurotoxin was recovered with an overall yield of 21.5%
and the purification factor increased to 216.7 fold. In addition, a mouse bioassay determined the purified neurotoxin
complex possessed a specific toxicity (LD50) of 4.095 ng/kg.
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Introduction
Botulinum neurotoxins (BoNTs), considered as the most toxic
substances in nature, are produced by the gram-positive and
endospore-forming anaerobic bacteria, Clostridium botulinum. These
toxins can be divided into seven serotypes (A–G) which are
structurally similar, yet antigenically distinct. BoNTs are translated
as a single 150-kDa polypeptide chain, which is post-translationally
processed by host or ectogenous proteases into a disulfide-linked di-
chain toxin consisting of a 50-kDa light chain and a 100-kDa heavy
chain protein. Generally, BoNTs are usually associated with non-
toxic neurotoxin-associated proteins (NAPs) such as hemagglutinin
and non-hemagglutinating proteins that are known as ‘‘progenitor’’
toxins[1].Thecompositionandsizesofthecomplexesorprogenitor
toxins can vary depending on toxin type. Whereas 12 S (300 kD),
16 S(500 kD)and19 S(900 kD)canbefoundintypeA[2],only12 S
canbedetectedintypeE[3].Furthermore,BoNT/Bcomplexescan
exist intwo forms, 12 S and 16 S[1].
Recently,similartoBoNT/Aprogenitortoxin,BoNT/Bhasbeen
used for treating patients with strabismus, blepharospasm, nystag-
mus,facialspasm,spasticaphonia,andmanyotherformsofdystonia
[4,5]. Clinical trials using the type B toxin can alleviate pain and
excessive muscle contraction associated with cervical dystonia
[6,7,8]. Furthermore, BoNT/B exhibited significantly less effects to
nearby and relatively distant non-injected muscles compared with
BoNT/A when doses were adjusted to produce an equivalent direct
effect.ThesefindingssuggestthatBoNT/Bmayofferadvantagesfor
modulating efficacy and safety of using this neurotoxin, which are
concerning issues incutaneous medicine and surgery.
For type A and B toxins, progenitor toxins are used during
treatment because they are easily obtained and are more stable
than the neurotoxin itself. Although the treatment is very effective,
serious side effects have been observed for some patients using
progenitor toxins. It was reported that using neurotoxin alone was
better than using progenitor toxin [9]. Generally, the purity of the
neurotoxin primarily depends on its intended use in different
applications. The highly purified neurotoxin is needed in many
applications, such as drug development and the use of the toxin
inhibitor as a research tool.
Previously published purification procedures for BoNTs typi-
cally includes acid or (NH4)2SO4 precipitations [10,11] and
affinity chromatography [9]. These methods are time-consuming
and may be inapplicable for industrial production. Therefore, a
new rapid purification process was developed in this study for
highly purifying BoNT/B by PEG precipitation and chromatog-
raphy. The obtained purified BoNT/B can be use for antibody
production, a toxoid vaccine, and a licensed drug.
Results
Growth Conditions and Toxin Production
The strains both exhibited higher growth rates and reached
higher peak cell densities when cultured in TPOM and TPGY
(Fig. 1). Cell lysis following stationary phase (12–20 h of growth)
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39670occurred in TPOM, TPM and TPGY. However, significant
differences in cell lysis were observed when culturing strain in
TPGY, TPOM and TPM. Additionally, the strains lysed poorly in
TPGY and more extensively in TPM and TPOM.
The concentrations of the BoNT complex were determined in
cell-free culture supernatants at each indicated time point (Fig. 2A–
C). For the strain in the three media, maximum extracellular toxin
levels were observed after about 32 hours, and extracellular toxin
levels continued to increase with more lysis at 20 ,32 hours. Cell
lysis of the strain was much greater in TPOM than in TPM or
TPGY at 96 h, and larger quantities of toxin in culture
supernatants correlated with extensive cell lysis. Toxin levels by
ELISA were approximately 2-fold greater in TPOM than in
TPGY or TPM after 96 h of growth (Fig. 2A–C). Overall, the
strain in TPOM expressed markedly higher toxin levels than in
TPM or TPGY.
PEG Precipitation
After the initial PEG precipitation, residual bacterial cells,
nucleic acids and some impurity proteins were removed (data not
shown). During the second step of PEG precipitation, highest
recovery of BoNT/B occurred using 0.3 M NaCl than 0.1 M
NaCl (Fig. 3A–B). For both concentrations of NaCl (0.1 M and
0.3 M), the concentration of PEG used was a primary factor
during the recovery and purification of the redissolved BoNT/B
within a certain range. However, when 0.1 M NaCl was used
during the purification, the pH played a role in the recovery of
BoNT/B, which was similarly seen when using 0.3 M NaCl at
20%–30% (w/v) PEG-6000 (Fig. 3B). Therefore, both ionic
concentration and pH had influence on the recovery of BoNT/B
during PEG precipitation, but the concentration of PEG played a
vital role in the recovery. Precipitation with high PEG concen-
tration (25% PEG-6000) resulted in a higher recovery using
0.1 M NaCl and pH 7.0 (Fig. 3A). However, a higher recovery
rate occurred at the expense of increased impurities in the
redissolved BoNT/B. Therefore, the final optimized condition
used 20% (w/v) PEG-6000, pH 5.0 and 0.3 M NaCl. The
recovery rate was at 87% and the purification factor was 61.5 fold
(Table 1), and parts of the impurity proteins and nucleic acids
could be removed using these optimized conditions.
Size-exclusion Chromatography (SEC)
After PEG precipitation, the redissolved protein supernatant
was concentrated to enhance resolution and minimize the volume
applied to the SEC column. The data showed that the SEC elution
profile included a single–larged and well-formed early eluting peak
corresponding to the high molecular weight BoNT/B complex at
pH 5.8 (Fig. 4A). However, at pH 8.0, the SEC elution profile
included a high early eluting peak corresponding to the high
molecular weight BoNT/B, and some small peaks corresponding
to contaminants (Fig. 4B). The fraction contained a toxicity of
2.88610
6 MLD/mL. The yield of SEC was up to 42.5%, and the
purification factor was 108.5 fold (Table 1). The remaining
impurities were removed by employing hydrophobic interaction
chromatography (HIC).
Hydrophobic Interaction Chromatography (HIC)
The fractions containing the interested protein were pooled and
passed through hydrophobic interaction chromatography using a
Phenyl HP column. An optimal pH of 5.8 was used to purify the
BoNT/B complex. The column was washed with 4,5 bed
volumes of buffer A to remove all the unbound proteins. The
results showed that an optimized stepwise gradient of 0.6 M,
0.2 M, and 0 M of ammonium sulphate into a Phenyl HP column
(Fig. 5A) was most effective for isolating the BoNT/B complex.
The fraction containing the BoNT/B complex was eluted using
0.6 M of ammonium sulphate. The fractions obtained were
analyzed by SDS-PAGE (Fig. 6).
An optimal pH of 8.0 was used to purify BoNT/B. The
retention and elution of BoNT/B was optimized with a further
increase in its purity by decreasing the levels of ammonium
Figure 1. Growth patterns of C. botulinum type B strain. It indicates the optical density of the cultures in three media.
doi:10.1371/journal.pone.0039670.g001
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chromatograms are given in Fig. 5B. The BoNT/B was eluted at
an ammonium sulfate concentration between 0.8 and 0.6 M. Most
of impurities were eluted in the flow-through fractions and at the
first major peak. The purity was determined at 95% by SDS-
PAGE (Fig. 7).
In this study, HIC was used as the final purification step. The
final product contained a toxicity of 1.25610
7 MLD/mL. The
final recovery of the purification was up to 21.5% and the
purification factor was 216.7 fold (Table 1).
Mouse Toxicity of BoNT/B Complex
The LD50 of BoNT/B using Karber’s method was 4.095 ng/kg
(about 0.0901 ng/mouse) with a 95% confidence limit between
3.077 and 5.468 ng/kg. Deaths occurred in most cases between 12
and 48 h after dosing (Fig. 8), with mortalities also observed at a
low dose of 0.125 and 0.0675 ng/mouse after 48 h. At a high
dosage (0.5 ng/mouse, filled circles), BoNT/B caused more rapid
lethality compared to the low dosage. Surviving mice that received
a dosage of BoNT/B displayed classic symptoms of botulism
including ruffled fur, wasp-waist, hind limb paralysis and labored
breathing compared to control mice [12,13]. These results
provided information for the toxicity of BoNT/B given by
intraperitoneal injection.
Discussion
It is necessary that BoNT/B can be consistently highly
produced for its purification. The growth and the production of
biologically active BoNTs and BoNT complexes are known to vary
with the strains of C. botulinum, medium compositions, and culture
conditions [14]. Inconsistent batch-to-batch production of the
same strain has been described, including C. botulinum type A [15].
To better optimize the conditions for BoNT/B production, the
kinetics of C. botulinum strain growth and BoNT/B production is
needed to be clearly defined. In this study, the growth of C.
botulinum strain and BoNT/B production differed in TPOM,
TPGY and TPM. A higher concentration of BoNT/B was
obtained from TPOM supernatant (see Fig. 2), which correlated
with a higher rate of cell lysis.
PEG precipitation is a crude and non-specific technique that
separates proteins by their solubility. PEG acts as an inert solvent
sponge and reduces solvent availability. Protein concentration is
increased upon increasing concentrations of PEG until the
solubility is exceeded and precipitation occurs [16]. In this study,
the crude BoNT/B was extracted by PEG precipitation. PEG
precipitation not only removes the contaminant, but is stable as
PEG precipitates that can be resuspended to concentrate the
dissolve BoNT/B. To achieve this, we used 20% (w/v) PEG-6000,
pH 5.0 and 0.3 M NaCl, and reported a recovery rate of BoNT/B
complexes up to 87%.
Notably, BoNT/B is produced as BoNT/B complexes in which
the neurotoxin component is non-covalently linked with non-toxic
proteins. As mentioned previously, BoNT complexes are stable
only at slightly acidic pH range of 5,7 [17,18], and can dissociate
in alkaline solutions (pH values .7) [19,20]. In this study, for the
purification of BoNT/B and BoNT/B complexes, the first
purification step was a SEC at pH 8.0 and pH 5.8, respectively.
At pH 8.0, the complex dissociated and could partly be separated
within this step (Fig. 4B). Indeed, in this step, some small impurity
proteins and parts of nucleic acid were removed with a
Sephacryl
TM S-100 size column.
Furthermore, for further purification to remove most of the
nucleic acids and some impure proteins, HIC was performed with
a phenyl HP column. In HIC, both the hydrophobic ligand types
and salt concentration in solution could influence chromatograph-
ic resolution. HIC has also been used as an effective purification
Figure 2. Determination of botulinum toxin type B expression
in C. botulinum strain grown in three media. A, TPOM; B, TPM; C,
TPGY. Botulinum toxin concentration was determined in culture
supernatants by ELISA.
doi:10.1371/journal.pone.0039670.g002
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[21,22]. In contrast to other chromatographic techniques, HIC is
viewed as a relatively gentler procedure, leading to its widespread
use in downstream purification of biopharmaceuticals [23].
Optimal purification of BoNT/B and BoNT/B complexes was
observed using a stepwise and gradient elution by a Phenyl HP
column. The purity was determined to be 95% by SDS-PAGE
(Fig. 7).
A new rapid purification process was developed in this study for
highly purified BoNT/B by PEG precipitation and chromatogra-
phy that required less time (9 days) than a previously published
method (at least 11 days) [11]. Compared with acid or (NH4)2SO4
precipitation, PEG precipitation is a gentle method to extract
proteins and contribute for protecting protein activity. Particular-
ly, PEG precipitation can remove residual bacterial cells, and parts
of impurified proteins and nucleic acids. This new efficient
procedure could be applicable for the purification of other types of
toxin.
The ‘‘gold standard’’ for the detection and measurement of
BoNTs is the intraperitoneal mouse bioassay [13,24]. In this study,
this bioassay was used to test the toxicity of purified the BoNT/B
complex. The data indicated that a higher dose killed more
effectively and sufficiently than a lower dose, and the LD50 of
BoNT/B calculated by the Karber’s method was 4.095 ng/kg.
These results provided information for the toxicity of BoNT/B given by
intraperitoneal injection, but it had been reported that the toxicity of BoNT/B
is lower than that of BoNT/A [25], and we obtained a similar result with the
purified BoNT/B.
In summary, the kinetics of C. botulinum strain growth and
BoNT/B production were optimized for maximum yield, and
TPOM was the more suitable culture for its growth and
production. The purification method for BoNT/B and BoNT/B
complex was standardized after PEG precipitation and two
chromatographic runs under various conditions. PEG precipita-
tion coupled with chromatography is a rapid and efficient method
to purify BoNT/B and its associated complex compared to acid or
(NH4)2SO4 precipitation. Therefore, it is hopeful that this method
could be used for the purification of other types of toxin, vaccine
production and synthesis of BoNT for pharmaceutical purposes, as
well as for the fundamental studies of the structure and function of
BoNT.
Materials and Methods
Chemicals and Bacterial Strain
Polyethylene glycol (PEG, MW: 6000 kDa) was purchased from
Merck. Ammonium sulfate ((NH4)2SO4), potassium phosphate
dibasic anhydrous (K2HPO4), sodium phosphate monobasic
anhydrous (NaH2PO4) and sodium chloride (NaCl) were obtained
from Sigma. All other chemicals were of analytical grade.
The type B botulism antitoxin (equine) was provided by the
Lanzhou Institute of Biological Products, Lanzhou, China. The C.
Figure 3. Recovery of BoNT/B by PEG precipitation with various concentrations of PEG at various pH values. A, NaCl concentration:
0.1 M; B, NaCl concentration: 0.3 M. Recovery was defined as the ratio of the amount of BoNT/B measured by ELISA in PEG precipitation to that in the
starting material.
doi:10.1371/journal.pone.0039670.g003







(MLD/mL) Yield (%) Purification
c (fold)
Culture supernatant 25 1.5610
5 2 1
PEG precipitation 21.75 1.3610
7 87 61.5
Size-exclusion chromatography 10.625 2.88610
6 42.5 108.5
Hydrophobic interaction chromatography 5.375 1.25610
7 21.5 216.7
aThe concentration of total BoNT/B complex was determined by a ‘‘sandwich’’ ELISA method using the purified BoNT/B as a standard. And the purified BoNT/B
concentration was determined by BCA assay.
bMinimum lethal dose (MLD) was defined as the minimum dose required to kill two mice as described in Materials and Methods.
cThe purification factor was estimated by the mouse toxigenicity test of BoNT/B complex.
doi:10.1371/journal.pone.0039670.t001
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State Key Laboratory of Pathogens and Biosecurity, Beijing,
China and used in this study.
Production of the BoNT/B
The C. botulinum type B strain was cultured in three different
types of media, including TPYG (5% trypticase peptone, 0.5%
bacto peptone, 0.4% glucose, 2% yeast extract and 0.1% L-
cysteine, pH 7.4), toxin production medium (TPM, 2% casein
hydrolysate, 1% yeast extract, and 0.5% glucose, pH 7.2), and
optimized medium of toxin production (TPOM, yeast extract
1%, casein hydrolysate 2%, Na-thioglycolic acid 0.05%, L-
cysteine HCL 0.1% and glucose 0.5% pH 7.2).
The C. botulinum type B strain stored at 280uC was inoculums
(0.5 ml) for 25 ml of cooked meat media (peptone 3%, yeast
extract 0.5%, beef extract 0.5%, glucose 0.3%, NaH2PO4 0.5%,
pH 7.2,7.4) incubated at 37uC. Three 1 L glass carboys each
containing 1 L of three different culture mediums were autoclaved
20 min. The three carboys cooled down overnight to 30uC were
individually inoculated with 10 ml of active culture growing in the
cooked meat medium and incubated undisturbed for 96 hours at
30uC.
The cultures were sampled every 2 hours for 28 hours and
every 4 hours in subsequent 68 hours. At each time point, the
OD600 was measured and samples were analyzed for detection
of BoNT/B by Enzyme-linked immunosorbent assay (ELISA).
Extraction of the BoNT/B using PEG Precipitation
After 96 hours of culture, BoNT/B was extracted from
cultured media using the following steps. First, the condition of
initial PEG precipitation was 5% (w/v) PEG-6000 and pH 6.8.
After 5,6 hours of precipitation, the culture media was
Figure 4. Purification of toxins using size-exclusion chromatography with Sephacryl
TM S-100 size column. A, The BoNT/B complex was
eluted with buffer at pH 5.8; B, the purification of the BoNT/B was running with buffer at pH 8.0.The arrow shows the activity fraction.
doi:10.1371/journal.pone.0039670.g004
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Second, for the supernatant from the initial PEG precipitation,
the effects of PEG concentration, ionic intensity and PH on
PEG precipitation were optimized by full factorial experiment.
The pH of the supernatant was adjusted to the desired level
with 1 mol/L Tris-HCl using a pH electrode (Mettler Toledo
SG2). The PEG 6000 was added very slowly with stirring at a
50% (w/v) stock solution to the desired final concentration.
After 30 min of stirring, the supernatant was stored overnight at
4uC. The supernatant was centrifuged at 10,000 g for 20 min.
The supernatant was decanted and the protein pellets were
collected. Pellets were resuspended in one-third of the initial
volume in a solution of 50 mM Tris–Bis (pH 5.8 for production
of BoNT/B complex and pH 8.0 for BoNT/B). Undissolved
protein was then removed by a second centrifugation at
10,000 g for 15 min. These conditions must be carefully
followed for reproducible results.
Size-exclusion Chromatography (SEC)
If otherwise stated, A ¨KTA FPLC and resins for chromato-
graphic purification were supplied by GE Healthcare. All
chromatography steps were performed at room temperature.
After PEG precipitation, the concentrated and pre-purified and
resuspended toxin supernatant obtained in the precipitation step
was subjected to size-exclusion chromatography using a HiPrep
Sephacryl
TM S-100 column. The running buffer for this column
was 50 mM Tris–Bis, 150 mM NaCl, and the pH of the buffer
was 5.8 and 8.0 for the purification of BoNT/B and BoNT/B
complex, respectively. Fractions were collected from the column at
1 ml/min. Their absorbance was measured at 280 nm, and the
Figure 5. Further purification of toxins using hydrophobic interaction chromatography. Pooled fractions obtained from the Sephacryl
TM
S-100 size column (Fig. 4) were applied to a phenyl HP column. A, The BoNT/B complex was eluted at pH 5.8; B, the BoNT/B was purified at pH 8.0.
The arrow shows the activity fraction.
doi:10.1371/journal.pone.0039670.g005
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below.
Hydrophobic Interaction Chromatography (HIC)
After SEC, fractions containing the toxin were subjected to
hydrophobic interaction chromatography (HIC) using a Hi-
Trap
TM Phenyl HP 5- ml column that equilibrated with 3,4
bed volumes of buffer A (50 mM Tris–Bis, 0.05 mM EDTA,
pH 5.8 or 8.0, and 1 M ammonium sulfate). Flow rate was
5 ml/min. In order to purify the BoNT/B and BoNT/B
complex, the pH of the buffer and elution condition were
optimized. After washing the column with starting buffer A, the
bound protein was eluted either by multi-step elution (e.g. 700,
600, 500, 200 and 0 mM ammonium sulfate) or by gradient
elution using a 1,0 M gradient of ammonium sulfate in 50 mM
Tris–Bis buffer containing 0.05 mM EDTA. The fractions
obtained were examined at 280 nm, and the sample was
analyzed by SDS-PAGE and ELISA.
Purified Complex Toxin and Neurotoxin Analysis by SDS-
PAGE
The purity of botulinum toxins in purified or crude toxin
samples was estimated by SDS-PAGE. A 2% stacking and 10%
separating vertical gel was used in the Mini Protean II-system (Bio-
Rad) with high molecular weight marker (NEB) as a standard. The
separation was run at a constant voltage of 180 V for
approximately 50 min. Gels were Coomassie-stained and digital
images were analyzed using BandScan software.
Detection and Quantification of BoNT/B using ELISA
To calculate the overall recovery of the toxin, the toxin
concentration was determined by a ‘‘sandwich’’ ELISA method.
The BoNT/B is captured on the plate by the botulinum antitoxin.
A polyclonal antibody specific for BoNT/B from our laboratory
[26] is then added into the plate, and can be detected by HRP-
conjugated goat anti-mouse IgG. Finally, the plate was developed
by adding a substrate to produce the colorimetric reaction, which
read the absorbance at 450 nm using the SpectraMAX Microplate
Reader (Molecular Devices). The absorbance indicates the
quantity of BoNT/B in the sample using the purified BoNT/B
as a standard. The determination of purified BoNT/B and total
protein concentration use BCA assay. BCA Protein Assay Kit
(Pierce) was used with bovine serum albumin as the protein
standard.
Mouse Bioassay
The biological activity of the BoNT/B complex solutions was
determined in BALB/c mice weighing 18,22 g, that were
randomized and inoculated intraperitoneally (i.p.) with 500 mlo f
sample. Groups of ten mice were used at each dosage level and
four or five dose levels were tested per experiment. For nicking of
the neurotoxin, trypsin was added to a final concentration of
20 mg/ml mixed and incubated at 37uC for 30 min. Serial 2-fold
dilutions were then made in gelatine-phosphate-buffer (GPB:
50 mM PBS, 0.2% gelatin, and pH 6.8). The animals were
observed for death over a period of 4 days. 50% lethal dose (LD50)
values were calculated using the Karber’s method [27]. Minimum
lethal dose (MLD) was defined as the minimum dose required to
kill two mice [13]. A survival curve of mice treated i.p. with
BoNT/B complex was determined using the Prism 4 statistics
software (Graph Pad Software Inc.).
All mice were housed in pathogen free conditions with free
access to food and water. The animal use protocol was conducted
in compliance with the Guide for the Care and Use of Laboratory
Animals and the Association for Assessment and Accreditation of
Laboratory Animal Care International, and including the relevant
local animal welfare bodies in China. In addition, the permit
number of all animal work was SCXK-(JUN) 2007-004 that
approved by the animal ethics committee of Beijing Institute of
Microbiology and Epidemiology.
Figure 6. SDS–PAGE analysis of the purified BoNT/B complex.
1,3, BoNT/B complex (diluted 1:2 with sample buffer containing DTT)
after purification by hydrophobic interaction chromatography column;
M, high molecular markers.
doi:10.1371/journal.pone.0039670.g006
Figure 7. SDS–PAGE analysis of the purified BoNT/B. 1,3, BoNT/
B after purification by hydrophobic interaction chromatography
column; M, markers.
doi:10.1371/journal.pone.0039670.g007
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